Why Trial Success and FDA Approval Odds Diverge

A Kalshi market on whether a biotech trial meets its primary endpoint is not an FDA approval forecast. Trial odds cover a specified clinical result; approval odds can also reflect filing, regulatory review and the risk that no qualifying FDA decision arrives before the contract deadline. A lower approval probability can therefore be entirely consistent with higher trial-success odds.

Enter the trial and conditional probabilities; the tool calculates the implied approval-by-deadline chance.

Trial and Approval Contracts Measure Different Events

Kalshi and AppliedXL announced their biotech pilot in July 2026 with separate contracts for clinical-trial outcomes and FDA decisions. The announcement said markets would resolve from named public records, such as a registered primary endpoint, an FDA approval letter or an advisory-committee vote record. It also said the pilot was limited to late-stage trials after enrollment had closed (Kalshi/AppliedXL announcement).

The contract’s exact rules—not the drug’s general prospects—define the forecast:

Market Type	Typical YES Condition	What YES Does Not Establish
Trial outcome	A named study meets its registered primary endpoint	The drug is safe overall, will be submitted promptly or will receive approval
Advisory-committee vote	The committee produces the specified favorable vote	FDA will approve; committee recommendations are nonbinding
FDA decision	FDA grants the specified form of approval by the deadline	Every trial succeeded, the label is as broad as expected or approval came without conditions

For example, the registered POLARIS-AD Phase 3 study of AR1001 identifies change in Clinical Dementia Rating Scale–Sum of Boxes at 52 weeks as its primary outcome. Safety and several cognitive, functional and biomarker measures are listed separately (ClinicalTrials.gov record NCT05531526). A contract tied to that primary outcome can resolve YES without deciding every issue FDA would consider.

FDA describes a marketing application as a much larger package containing preclinical and clinical evidence, proposed labeling, safety updates and other information. Reviewers may inspect trial sites, request answers based on existing data or require additional studies before approval (FDA drug-review overview).

An advisory-committee contract represents another distinct event. FDA says a committee’s recommendation is advice rather than a binding decision (FDA advisory-committee overview). A favorable vote can therefore settle one market YES while a later approval contract settles NO.

A Probability Tree Can Reconcile the Prices

Consider a hypothetical pair of markets observed at the same time:

• Trial meets its primary endpoint: 70%
• FDA approves the drug by a stated date: 48%

Those numbers do not conflict. Under the simplifying assumption that approval by the deadline requires success on this trial, one possible decomposition is:

1. A 70% chance that the trial meets its primary endpoint.
2. Conditional on that result, an 85% chance that the sponsor files and reaches a decision within the approval contract’s window.
3. Conditional on both events, an 80% chance that FDA grants the qualifying approval.

The calculation is 0.70 × 0.85 × 0.80 = 0.476, or about 48%.

This is a reading aid, not a full drug-development model. FDA can consider multiple studies and confirmatory evidence rather than only one endpoint. Its guidance discusses how one adequate and well-controlled investigation may be combined with confirmatory evidence to satisfy the effectiveness standard (FDA effectiveness guidance).

Safety findings, manufacturing, inspection results, labeling negotiations and timing can also separate the probabilities. The gap between 70% and 48% does not reveal how much probability the market assigns to each factor unless contracts isolate those intermediate events.

The reverse ordering can occasionally be coherent. An approval forecast might exceed the odds for one particular trial endpoint if the application rests on other evidence or the drug has another regulatory route covered by the approval rules. Prices should not be treated as inconsistent until the contract language establishes that one event is required for the other.

Deadlines Can Turn Eventual Approval Into NO

The pilot’s anito-cel contract illustrates why the settlement rules matter. Its YES condition is full or accelerated FDA approval in 2026. It resolves NO for a complete response letter, sponsor withdrawal, “conditional approval,” or no decision within the specified period (Kalshi market record).

That makes it an approval-by-deadline forecast, not an eventual-approval forecast. A delay into 2027 can produce a NO even if FDA later approves the therapy. “Full or accelerated approval” is also narrower than a general claim that regulators responded favorably.

Before comparing a trial price with an approval price, align six parts of the contracts:

1. Entity: Both contracts should cover the same drug, indication and sponsor.
2. Event: Identify whether each contract asks about an endpoint, filing, committee vote or approval.
3. Evidence source: Check which registry entry, FDA document or vote record controls settlement.
4. Deadline: Determine whether no decision by the specified date produces NO.
5. Approval type: Check whether full, accelerated or other regulatory actions qualify.
6. Snapshot: Record both prices at the same time and before the same news.

A comparison that fails any of these checks may be measuring different information rather than disagreement between traders.

Executable Quotes Can Differ From the Displayed Probability

In the anito-cel API record captured on September 29, 2026, YES had an 86-cent bid and 92-cent ask, while the last trade was 85 cents. The same record reported about 3,630 contracts of cumulative volume. Treating the market as one precise, executable approval probability would hide the six-cent spread and the possibility that the last trade was stale.

The bid represents the quoted level at which a trader could sell YES, subject to available depth. The ask is the quoted level for buying YES. A displayed last price is a record of a previous transaction, not necessarily a currently executable quote.

A useful market snapshot therefore records the bid, ask, last trade, available depth, cumulative volume and timestamp. It should keep three concepts separate:

• Forecast: The probability estimate inferred from the order book.
• Execution price: The price at which a trader could currently buy or sell.
• Payout condition: The contract wording that determines YES or NO.

Fees and slippage affect a trade’s economics, but they should not be casually added to the probability forecast. See prediction-market fees versus quoted price for the all-in-cost treatment.

The available anito-cel record does not provide a matching, same-time trial quote. Its figures can illustrate how to read an approval market, but they do not establish an observed trial-versus-approval probability gap for that therapy.

The Current Record Does Not Establish Biotech Calibration

Aligned trial and approval markets can show the combined probability loss between a specified clinical result and a qualifying regulatory decision. Additional contracts for filing, advisory votes or timing could help locate more of that attrition. A simple gap between two prices cannot identify its cause on its own.

Nor does one market show that Kalshi is calibrated in biotech. Calibration requires a sizable set of resolved contracts, probability snapshots collected under a consistent method, and separate evaluation of trial, committee and approval questions. One drug produces anecdotes, not a calibration curve.

The appropriate framework is covered in market calibration by platform and price bucket and Brier score versus calibration. Until enough comparable contracts resolve, the defensible interpretation is narrower: a biotech price estimates the contract’s written event by its written deadline, not whether a medicine generally “works” or will ever reach patients.